Baseline characteristics of the North American prodromal Synucleinopathy cohort
Annals of Clinical and Translational Neurology · 2023-04 · 10 (4) · 520-535
DOI: 10.1002/acn3.51738 ↗Kurz gefasst
Klinische Studie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 08.02.2023. Verfasst von Jonathan E Elliott und 23 weiteren Autor:innen. Beteiligte Einrichtung: VA Portland Health Care System, Research Service, Portland, Oregon, USA. Hauptthemen laut MEDLINE: Lewy Body Disease, Multiple System Atrophy, Parkinson Disease, REM Sleep Behavior Disorder. Die Arbeit wurde bisher 51-mal zitiert (Crossref) und nennt 61 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIA NIH HHS, RRD VA, U.S. Department of Veterans Affairs.
Abstract (Originalsprache)
Objective
Rapid eye movement (REM) sleep behavior disorder (RBD) is widely considered a prodromal synucleinopathy, as most with RBD develop overt synucleinopathy within ~10 years. Accordingly, RBD offers an opportunity to test potential treatments at the earliest stages of synucleinopathy. The North American Prodromal Synucleinopathy (NAPS) Consortium has created a multisite RBD participant, primarily clinic‐based cohort to better understand characteristics at diagnosis, and in future work, identify predictors of phenoconversion, develop synucleinopathy biomarkers, and enable early stage clinical trial enrollment.
Methods
Participants ≥18 years of age with overnight polysomnogram‐confirmed RBD without Parkinson's disease, dementia, multiple system atrophy, or narcolepsy were enrolled from nine sites across North America (8/2018 to 4/2021). Data collection included family/personal history of RBD and standardized assessments of cognitive, motor, sensory, and autonomic function.
Results
Outcomes are primarily reported based on sex (361 total: n = 295 male, n = 66 female), and secondarily based on history of antidepressant use ( n = 200 with, n = 154 without; with correction for sex differences) and based on extent of synucleinopathy burden ( n = 56 defined as isolated RBD, n = 305 defined as RBD+ [i.e., exhibiting ≥1 abnormality]). Overall, these participants commonly demonstrated abnormalities in global cognition (MoCA; 38%), motor function (alternate tap test; 48%), sensory (BSIT; 57%), autonomic function (orthostatic hypotension, 38.8%), and anxiety/depression (BAI and PHQ‐9; 39.3% and 31%, respectively).
Interpretation
These RBD participants, assessed with extensive history, demographic, cognitive, motor, sensory, and autonomic function demonstrated a lack of sex differences and high frequency of concomitant neurological abnormalities. These participants will be valuable for future longitudinal study and neuroprotective clinical trials.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Autor:innen und Institutionen
- VA Portland Health Care System, Research Service, Portland, Oregon, USA.
- Oregon Health & Science University, Neurology, Portland, Oregon, USA.
- Behavioral Neuroscience, Oregon Health & Science University, Portland, Oregon, USA.
- Department of Pulmonary and Critical Care Medicine, Oregon Health & Science University, Portland, Oregon, USA.
- Oregon Institute of Occupational Health Sciences, Oregon Health & Science University, Portland, Oregon, USA.
- Neurology, VA Portland Health Care System, Portland, Oregon, USA.
ORCID-Profile: Jonathan E Elliott, Miranda M Lim, Allison T Keil, Ronald B Postuma, Jean-François Gagnon, Erik K St Louis, Julie A Fields, Daniel E Huddleston, Donald L Bliwise, Michael J Howell, Susan R Criswell, Emmanuel H During, Mitchell G Miglis, David R Shprecher, Joyce K Lee-Iannotti, Bradley F Boeve, Yo-El S Ju
Förderung
- NIA NIH HHS
- RRD VA
- U.S. Department of Veterans Affairs
Zitieren
APA
Elliott, J. E., Lim, M. M., Keil, A. T., Postuma, R. B., Pelletier, A., Gagnon, J. F., St Louis, E. K., Forsberg, L. K., Fields, J. A., Huddleston, D. E., Bliwise, D. L., Avidan, A. Y., Howell, M. J., Schenck, C. H., McLeland, J., Criswell, S. R., Videnovic, A., During, E. H., Miglis, M. G., …, & North American Prodromal Synucleinopathy (NAPS) Consortium (2023). Baseline characteristics of the North American prodromal Synucleinopathy cohort. Annals of Clinical and Translational Neurology, 10(4), 520-535. https://doi.org/10.1002/acn3.51738
Vancouver
Elliott JE, Lim MM, Keil AT, Postuma RB, Pelletier A, Gagnon JF, et al. Baseline characteristics of the North American prodromal Synucleinopathy cohort. Annals of Clinical and Translational Neurology. 2023;10(4):520-535. doi:10.1002/acn3.51738
BibTeX
@article{Elliott2023,
author = {Elliott, Jonathan E and Lim, Miranda M and Keil, Allison T and Postuma, Ronald B and Pelletier, Amelie and Gagnon, Jean-François and St Louis, Erik K and Forsberg, Leah K and Fields, Julie A and Huddleston, Daniel E and Bliwise, Donald L and Avidan, Alon Y and Howell, Michael J and Schenck, Carlos H and McLeland, Jennifer and Criswell, Susan R and Videnovic, Aleksandar and During, Emmanuel H and Miglis, Mitchell G and Shprecher, David R and Lee-Iannotti, Joyce K and Boeve, Bradley F and Ju, Yo-El S and North American Prodromal Synucleinopathy (NAPS) Consortium, North American Prodromal Synucleinopathy (NAPS) Consortium},
title = {Baseline characteristics of the North American prodromal Synucleinopathy cohort},
journal = {Annals of Clinical and Translational Neurology},
year = {2023},
volume = {10},
number = {4},
pages = {520--535},
doi = {10.1002/acn3.51738}
}
EUVIMED